Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P13637: Variant p.Gly947Arg

Sodium/potassium-transporting ATPase subunit alpha-3
Gene: ATP1A3
Feedback?
Variant information Variant position: help 947 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glycine (G) to Arginine (R) at position 947 (G947R, p.Gly947Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In AHC2; strong decrease in ATPase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 947 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1013 The length of the canonical sequence.
Location on the sequence: help CKTRRNSVFQQGMKNKILIF G LFEETALAAFLSYCPGMDVA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         CKTRRNSVFQQGMKNKILIFGLFEETALAAFLSYCPGMDVA

Mouse                         CKTRRNSVFQQGMKNKILIFGLFEETALAAFLSYCPGMDVA

Rat                           CKTRRNSVFQQGMKNKILIFGLFEETALAAFLSYCPGMDVA

Chicken                       CKTRRNSVFQQGMKNKILIFGLFEETALAAFLSYCPGMDVA

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1013 Sodium/potassium-transporting ATPase subunit alpha-3
Transmembrane 942 – 960 Helical
Modified residue 933 – 933 Phosphoserine; by PKA



Literature citations
De novo mutations in ATP1A3 cause alternating hemiplegia of childhood.
Heinzen E.L.; Swoboda K.J.; Hitomi Y.; Gurrieri F.; Nicole S.; de Vries B.; Tiziano F.D.; Fontaine B.; Walley N.M.; Heavin S.; Panagiotakaki E.; Neri G.; Koelewijn S.; Kamphorst J.; Geilenkirchen M.; Pelzer N.; Laan L.; Haan J.; Ferrari M.; van den Maagdenberg A.M.; Zucca C.; Bassi M.T.; Franchini F.; Vavassori R.; Giannotta M.; Gobbi G.; Granata T.; Nardocci N.; De Grandis E.; Veneselli E.; Stagnaro M.; Vigevano F.; Oechsler C.; Arzimanoglou A.; Ninan M.; Neville B.; Ebinger F.; Fons C.; Campistol J.; Kemlink D.; Nevsimalova S.; Peeters-Scholte C.; Casaer P.; Casari G.; Sange G.; Spiel G.; Martinelli Boneschi F.; Schyns T.; Crawley F.; Poncelin D.; Fiori S.; Abiusi E.; Di Pietro L.; Sweney M.T.; Newcomb T.M.; Viollet L.; Huff C.; Jorde L.B.; Reyna S.P.; Murphy K.J.; Shianna K.V.; Gumbs C.E.; Little L.; Silver K.; Ptacek L.J.; Ferrari M.D.; Bye A.M.; Herkes G.K.; Whitelaw C.M.; Webb D.; Lynch B.J.; Uldall P.; King M.D.; Scheffer I.E.; Sisodiya S.M.; Mikati M.A.; Goldstein D.B.;
Nat. Genet. 44:1030-1034(2012)
Cited for: VARIANTS AHC2 TYR-137; PHE-137; LEU-140; ASN-220; ASN-274; PHE-333; SER-755; SER-773; ASN-801; ARG-806; SER-810; PRO-811; LYS-815; VAL-919 DEL; ARG-947; ASP-955 AND TYR-992; CHARACTERIZATION OF VARIANTS AHC2 PHE-137; PHE-333; ASN-801; PRO-811 AND LYS-815; Alternating Hemiplegia of Childhood mutations have a differential effect on Na(+),K(+)-ATPase activity and ouabain binding.
Weigand K.M.; Messchaert M.; Swarts H.G.; Russel F.G.; Koenderink J.B.;
Biochim. Biophys. Acta 1842:1010-1016(2014)
Cited for: CHARACTERIZATION OF VARIANTS AHC2 TYR-137; ASN-220; ASN-127; ASN-801; LYS-815 AND ARG-947; Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis.
Trump N.; McTague A.; Brittain H.; Papandreou A.; Meyer E.; Ngoh A.; Palmer R.; Morrogh D.; Boustred C.; Hurst J.A.; Jenkins L.; Kurian M.A.; Scott R.H.;
J. Med. Genet. 53:310-317(2016)
Cited for: VARIANT THR-320; VARIANT AHC2 ARG-947;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.